Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Launched by FAES FARMA, S.A. · Dec 14, 2007
Trial Information
Current as of September 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical history of Seasonal Allergic Rhinoconjunctivitis with seasonal onset and offset of nasal allergy symptoms
- • documentation of a positive skin test within one year of screening to Mountain Cedar allergen
- Exclusion Criteria:
- • significant medical condition
- • significant nasal abnormality
- • significant cardiac condition
- • recent infection
- • use of other allergy medication during the study
About Faes Farma, S.A.
Faes Farma, S.A. is a leading pharmaceutical company based in Spain, dedicated to the research, development, manufacturing, and commercialization of innovative healthcare solutions. With a robust portfolio that spans various therapeutic areas, including neurology, dermatology, and respiratory diseases, Faes Farma is committed to improving patient outcomes through high-quality medicines. The company emphasizes a strong focus on clinical research and collaboration, aiming to advance medical knowledge and deliver safe and effective treatments globally. Through its dedication to excellence and innovation, Faes Farma plays a pivotal role in the evolving landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Oklahoma City, Oklahoma, United States
San Antonio, Texas, United States
Austin, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Waco, Texas, United States
Waco, Texas, United States
Austin, Texas, United States
Austin, Texas, United States
Kerrville, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
Ander Sologuren, MD
Study Director
Faes Farma, S.A.
Paul Ratner, MD
Principal Investigator
Sylvana Research Associates
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials